Home > Gastroenterology > ECCO 2023 > ECCO 2023 Highlights Podcast

ECCO 2023 Highlights Podcast

Presented by
Dr Rachel Giles, Medicom
ECCO 2023

In this episode (16 min), Medicom’s correspondent covers 6 presentations from the 18th Congress of
ECCO (the European Crohn’s and Colitis Organisation), held March 1-4, 2023, in Copenhagen, Denmark.

  1. Early postoperative vedolizumab decreases postoperative endoscopic relapse in CD
    When started on vedolizumab within 4 weeks after resection, patients had a significantly lower
    likelihood to experience a recurrence of Crohn’s disease (CD) than on placebo. Also, remission was
    seen in significantly more vedolizumab patients after 6 months. The REPREVIO trial was intended to
    establish whether a treatment with vedolizumab starting shortly after an ileocolonic resection, would
    have a beneficial effect on the recurrence of CD.
  2. Long-term ozanimod treatment shows sustained response in UC
    After up to 3 years of ozanimod therapy for ulcerative colitis (UC), the benefit of treatment was
    maintained in a large proportion of patients. Compared with the already known safety profile, no
    unexpected events emerged during this period. The interim analysis of the phase 3 True North open-
    label extension (OLE) trial (NCT02531126) evaluated ozanimod in patients with moderate to severely
    active UC on about 3 years of continuous ozanimod treatment for efficacy and safety over time.
  3. Proton pump inhibitor use is associated with worse outcome of CD
    In patients with Crohn´s disease (CD), exposure to proton pump inhibitors (PPIs) is an independent risk
    factor for worse treatment outcomes and shorter survival. Therefore, the widespread use of these
    agents should be critically reassessed.
  4. Perinatal exposure to parental CD increases the risk in offspring
    Offspring exposed particularly to maternal Crohn’s disease (CD) early in life had a markedly increased
    risk of developing CD compared with those exposed to parental CD later in life. Babies with early
    contact had a higher intestinal permeability and an altered microbiome composition, which might
    explain their elevated risk.
  5. GLP-1-based therapy for diabetes: no increased IBD risk
    A prospective, nationwide, cohort study could not find an increased risk for the development of
    inflammatory bowel disease (IBD) that was linked to the treatment of type 2 diabetes with glucagon-
    like peptide-1 (GLP-1)-based therapies.
  6. Final, long-term ustekinumab efficacy results in UC
    The 4-year results of the UNIFI long-term extension (LTE) study show that ustekinumab is safe and
    effective over the whole time-period in patients with moderate to severe ulcerative colitis (UC). Most
    patients achieve a sufficient treatment effect with a dose interval of 12 weeks.

Posted on